⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5653794 | 0.85 | EPHX1 (0.44) | — | |
| SCHEMBL5328559 | 0.78 | — | — | |
| SCHEMBL7140181 | 0.78 | — | — | |
| SCHEMBL2138350 | 0.77 | EPHX1 (0.41) | — | |
| SCHEMBL13932592 | 0.77 | GABRR1 (0.41) | — | |
| SCHEMBL2762997 | 0.76 | TSHR (0.48) | — | |
| SCHEMBL10676865 | 0.76 | — | — | |
| SCHEMBL11360513 | 0.76 | — | — | |
| SCHEMBL28653093 | 0.76 | — | — | |
| SCHEMBL8796019 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-0497525-B2 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-0497525-B1 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5623057-A | IMMUNOGENIC PROTEIN COVALENTLY LINKED TO POLYSACCHARIDE DERIVED FROM STREPTOCOCCUS PNEUMONIAE | MERCK & CO., INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0497525-A2 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO. INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0467714-A1 | The class II protein of the outer membrane of neisseria meningitidis | MERCK & CO. INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0161188-B1 | COVALENTLY-MODIFIED BACTERIAL POLYSACCHARIDES, STABLE COVALENT CONJUGATES OF SUCH POLYSACCHARIDES AND IMMUNOGENIC PROTEINS WITH BIGENERIC SPACERS, AND METHODS OF PREPARING SUCH POLYSACCHARIDES AND CONJUGATES AND OF CONFIRMING COVALENCY | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4882317-A | SOLUBILIZATION | MERCK & CO., INC. (US) | 1989-11-21 | — | — | US | disclosed |
| US-4695624-A | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | MERCK & CO., INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0161188-A2 | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | disclosed |